<?xml version="1.0" encoding="UTF-8"?>
<p id="P81">Lamivudine was the first drug to be used as an alter native to IFN-Î± for the treatment of CHB.
 <sup>
  <xref ref-type="bibr" rid="R175">175</xref>,
  <xref ref-type="bibr" rid="R176">176</xref>
 </sup> In a double-blind study involving about 350 patients with CHB, lamivudine was associated with substantial histologic improvement, HBeAg antibody seroconversion, and ALT normalization.
 <sup>
  <xref ref-type="bibr" rid="R177">177</xref>
 </sup> However, relapses are common once treatment is discontinued.
 <sup>
  <xref ref-type="bibr" rid="R178">178</xref>
 </sup>
</p>
